Corbel et al., 2004 - Google Patents
Toxicity and potency evaluation of pertussis vaccinesCorbel et al., 2004
View PDF- Document ID
- 17202692927279016461
- Author
- Corbel M
- Xing D
- Publication year
- Publication venue
- Expert review of vaccines
External Links
Snippet
Current methods for determining the potency and toxicity of pertussis vaccines are outdated and require improvement. The intracerebral challenge test is effective for determining the potency of whole-cell vaccines but is objectionable on animal welfare and technical …
- 229960003599 Pertussis vaccines 0 title abstract description 54
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Corbel et al. | Toxicity and potency evaluation of pertussis vaccines | |
| Kerr et al. | Bordetella pertussis infection: pathogenesis, diagnosis, management, and the role of protective immunity | |
| Lun et al. | Role of suilysin in pathogenesis of Streptococcus suis capsular serotype 2 | |
| AU714493B2 (en) | Multivalent DTP-polio vaccines | |
| KR101784142B1 (en) | Neisseria meningitidis compositions and methods thereof | |
| Wu et al. | Protective immunity conferred by recombinant Pasteurella multocida lipoprotein E (PlpE) | |
| KR101584871B1 (en) | Non-lipidated variants of neisseria meningitidis orf2086 antigens | |
| Lee et al. | Outer membrane protein H for protective immunity against Pasteurella multocida | |
| JP2655583B2 (en) | Novel pertussis toxin variants, Bordetella strains capable of producing such variants and their use in developing anti-pertussis vaccines | |
| Potter et al. | Protective capacity of the Pasteurella haemolytica transferrin-binding proteins TbpA and TbpB in cattle | |
| Banerjee-Bhatnagar et al. | Expression of Neisseria meningitidis iron-regulated outer membrane proteins, including a 70-kilodalton transferrin receptor, and their potential for use as vaccines | |
| US6696065B1 (en) | Acellular pertussis vaccines and methods of preparation thereof | |
| Bowe et al. | Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin | |
| Ayalew et al. | Immunogenicity of Mannheimia haemolytica recombinant outer membrane proteins serotype 1-specific antigen, OmpA, OmpP2, and OmpD15 | |
| Podda et al. | Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa | |
| Davies et al. | Outer-membrane protein and lipopolysaccharide variation in Pasteurella haemolytica serotype A1 under different growth conditions | |
| RU2252224C2 (en) | Peptide with neisseria meningitidis antigene activity, polynucleotide encoding the same, vaccine for prevention and treatment of diseases and conditions induced by neisseria meningitidis, (variants), antibody coupling with said peptide | |
| WO2020201985A1 (en) | Compositions and methods for eliciting an immune response against clostridium difficile | |
| Kolybo et al. | Immunobiology of diphtheria. Recent approaches for the prevention, diagnosis, and treatment of disease | |
| ROBBINS et al. | Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine | |
| Yu et al. | Analysis of the immunological responses to transferrin and lactoferrin receptor proteins from Moraxella catarrhalis | |
| CA2719041C (en) | A method for identifying polypeptides which comprise a cross-reactive antigenic determinant | |
| Coppens et al. | Production of Neisseria meningitidis transferrin-binding protein B by recombinant Bordetella pertussis | |
| Brennan et al. | Recent advances in the development of pertussis vaccines | |
| Heron et al. | DTaP vaccines from North American Vaccine (NAVA): composition and critical parameters |